Search PubMed⌕ Search

Biomedical subjects

N Brock

Publications and source records attributed to N Brock.

At least 19 recordsLinked to original sources
PubMed2000

[In Process Citation]

The development of oncological therapeutic agents is a complex and risky process and it is mainly pursued by research-based pharmaceutical companies. Academic and public research institutions, however, have contributed to the finding and evaluation of basic scientific knowledge, which were transferred to the industry for co-development. Since 1960 increasing regulatory demands have caused a prolonged development time and dramatical multiplication of costs. Oncological research in Germany began shortly after the end of war, when Bayer worked on the ethyleneimino compounds with agents like E39 and trenimon for therapeutical use. Early in the fifties this focus of research changed to Asta-Werke, Bielefeld (later ASTA Medica, Frankfurt) where cyclophosphamide (Endoxan, Cytoxan), ifosfamide (Holoxan, Ifex) and trofosfamide were developed as worldwide leading alkylating cytotoxic agents. The detection of mesna (Uromitexan, Mesnex) used for the organospecific detoxification of urotoxic metabolites caused a further increase of the cancerotoxic selectivity and an improved safety of oxazaophosphorine therapy. There has been ongoing research on alkylating agents (mafosfamide, glufosfamide), and new therapeutic principles like miltefosine (Miltex) or hormonal agents like cetrorelix (LHRH-antagonist) are in development.

Journal Article↗
PubMed1992

Hospital-acquired wound mucormycosis.

Cutaneous infections due to fungi of the order Mucorales are uncommon and usually present as a fulminant necrotizing cellulitis. We describe a case of a progressive wound infection at a surgical drain site caused by Rhizopus rhizopodoformis. The indolent nature of the infection and lack of systemic toxicity were atypical features. Mucormycosis should be suspected in cases of slowly progressive cellulitis in the appropriate clinical setting.

Cross Infection↗
PubMed1991

Pulmonary complications of combination therapy with cyclophosphamide and prednisone.

Oral cyclophosphamide and prednisone are standard treatment for some neoplasms and necrotizing systemic vasculitis and are advocated with increasing frequency for idiopathic interstitial lung disease. During a 15-month period, we observed four cases of acute respiratory failure from Pneumocystis carinii pneumonia (PCP) in patients treated with oral cyclophosphamide and prednisone. One patient each had polyarteritis nodosa, Wegener's granulomatosis, bronchiolitis obliterans with organizing pneumonia, and chronic lymphocytic leukemia with red blood cell aplasia. Hypoalbuminemia (serum albumin level less than 3.0 g/dl) and daily therapy were associated with increased risk for development of PCP (p less than 0.05). None of the patients had leukopenia (less than 3,500/cu mm) or neutropenia (less than 1,000/cumm) at diagnosis. All were negative for the human immunodeficiency virus. Patients receiving oral cyclophosphamide and prednisone may be at higher or increasing risk for PCP. A high index of suspicion and aggressive evaluation for opportunistic infection are needed in these patients; consideration for trimethoprim-sulfamethoxazole prophylaxis and development of more quantitative measures of immunosuppression are needed.

Aged↗
PubMed1989

Blood pressure response to tourniquet use in anesthetized horses.

Blood pressure during anesthesia and surgery was compared for 2 groups of horses. Group A, consisting of 23 horses, had a tourniquet placed on the distal portion of a limb. The other group of 20 horses (group B) had surgery of comparable nature and duration as did group-A horses, but a tourniquet was not used. There was a statistical difference (P less than 0.05) in the peak systolic arterial blood pressure between the groups; group-A horses had a mean (+/- SEM) peak of 151 +/- 6 mm of Hg and group-B horses had a peak of 118 +/- 4 mm of Hg. In addition, group-A horses had immediate decrease in blood pressure, coincident with tourniquet deflation. The blood pressure decrease of 23 +/- 3 mm of Hg represented 16% of immediate predeflation blood pressure. Comparable blood pressure decrease was not observed at the end of surgery in group-B horses. Significant difference was not found when other factors that could affect blood pressure were considered. These factors included preanesthetic medication, anesthetic agents, mode of ventilation, pretourniquet inflation blood pressure, and duration of tourniquet inflation. Significant (P less than 0.05) difference in peak blood pressure was observed when the tourniquet was placed on the dependent, compared with the uppermost, limb, with changes more pronounced when the tourniquet was placed on the dependent limb. Tourniquet placement was associated with hypertension, and tourniquet deflation was associated with blood pressure decrease in these anesthetized horses.

Analysis of Variance↗